Business Standard

Saturday, December 21, 2024 | 09:51 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Hindustan Antibiotics seeks redemption amid rising anti-China sentiments

The firm is charting a turnaround plan by beginning the manufacturing of key bulk drugs that the government has identified under a production-linked incentive (PLI) scheme

drug, medicine, drugs, pharma, pharmaceutical
Premium

The government is moving fast on incentivising API production. India imports 70 per cent of its API requirement from China now

Sohini Das Mumbai
Rising anti-Chinese sentiments and India’s search for alternative sources of bulk drugs have come as booster dose for sick public sector enterprises like Hindustan Antibiotics (HAL).
 
The firm is charting a turnaround plan by beginning the manufacturing of key bulk drugs that the government has identified under a production-linked incentive (PLI) scheme.
 
Speaking to Business Standard, Nirja Saraf, managing director of HAL, said: “We have requested the government to review the decision to go for a strategic sale of HAL.”
 
The PSU is planning to invest Rs 20 crore (requirement for the newly announced PLI scheme) to augment its production

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in